Escultor Omar Ortiz, discípulo y custodio de la obra de Rafael López del Campo, exige que el Museo de Arte de Puerto Rico honre al artista y exhiba la pieza “Borinquén” tras 26 años ausente (AUDIO)

Background As artificial intelligence (AI) continues to advance, its integration into mental healthcare offers both promise and uncertainty. Digital therapists have shown effectiveness in reducing s.....

YouTube video by Capr!

What did the FDA's three-month extension add to the deramiocel BLA? 24-month HOPE-3 data, a narrower proposed indication, a November 22, 2026 PDUFA. $CAPR

Capricor Therapeutics faces a class action lawsuit as shareholders question the integrity of the Phase 3 HOPE-3 trial. Key deadlines loom for investors looking to recover losses.

Capricor Therapeutics (CAPR) will present 24‑month data from the Phase 3 HOPE-3 trial and its open-label extension of Deramiocel in Duchenne muscular dystrophy at the 2026 World Muscle Society Congress in Hiroshima, Japan.The late-breaking presentations will include skeletal muscle and cardiac outcomes, a delayed-start analysis and natural history comparisons that were included in a recent major amendment to the Deramiocel BLA, which has a PDUFA target action date of November 22, 2026. HOPE-3 randomized 106 patients; 82 reached 24 months (40 originally on Deramiocel, 42 on placebo). The trial met its primary endpoint, with Deramiocel slowing decline in upper limb function by 54% versus placebo on PUL 2.0 (p=0.03). Capricor will also present two preclinical posters from its StealthX exosome platform.

Investors in Capricor Therapeutics, Inc. (CAPR) who suffered losses may now lead a crucial securities fraud lawsuit, with key deadlines approaching.

B. Riley upgrades Capricor to Buy from Neutral and lifts its target to $21 from $5 ahead of the Nov. 22, 2026 deramiocel FDA date.

The Mercury Capri IMSA GT Race Car features Lyn St. James history, a 338ci dry sump V8, Jerico four speed gearbox and tube frame chassis.

Investors in Capricor Therapeutics have been notified of a class action lawsuit alleging securities fraud. Significant deadlines are approaching for claims.